Past, Present and Future of Oncolytic Reovirus.
Past, Present and Future of Oncolytic Reovirus.
复制标题
DOI：
10.3390/cancers12113219
复制
发表时间：
2020-10-31
期刊：
影响因子：
5.2
通讯作者：
Errington-Mais F
中科院分区：
文献类型：
--
作者：
Müller L;Berkeley R;Barr T;Ilett E;Errington-Mais F
在这篇综述文章中，作者对临床配制为 pelareorep 的溶瘤病毒、呼肠孤病毒进行了公正的综述。特别是，作者总结了呼肠孤病毒溶瘤的分子和细胞要求的已知信息，并提供了呼肠孤病毒诱导的抗肿瘤免疫反应的全面总结。重要的是，该综述还概述了更有效的联合疗法及其在临床试验中的评估所取得的进展。还讨论了利用呼肠孤病毒的全部潜力仍然存在的局限性和挑战。近年来，溶瘤病毒疗法 (OVT) 受到了极大关注，特别是自 2015 年美国食品和药物管理局 (FDA) 批准 talimogene Laherparepvec (T-VEC) 以来。溶瘤病毒 (OV) 的机制研究表明，大多数（如果不是全部）OV 会诱导直接溶瘤并刺激先天性和适应性抗肿瘤免疫。随着肿瘤建模的进步，可以表征肿瘤微环境（TME）成分的影响并识别细胞死亡所需的细胞机制（直接溶瘤和抗肿瘤免疫反应），很明显，“一刀切”的方法并不适用于所有 OV，或者实际上适用于不同肿瘤类型和疾病部位的相同 OV。本文将对溶瘤呼肠孤病毒（临床上称为 pelareorep）进行公正的综述，包括呼肠孤病毒溶瘤和抗肿瘤免疫的分子和细胞要求、临床前疗效报告及其总体临床轨迹。此外，由于现在非常清楚，包括呼肠孤病毒在内的所有 OV 的真正潜力只有在开发协同组合策略时才能发挥，因此将讨论呼肠孤病毒组合疗法，包括充分利用这种有前途的治疗剂潜力所面临的限制和挑战。
Within this review article the authors provide an unbiased review of the oncolytic virus, reovirus, clinically formulated as pelareorep. In particular, the authors summarise what is known about the molecular and cellular requirements for reovirus oncolysis and provide a comprehensive summary of reovirus-induced anti-tumour immune responses. Importantly, the review also outlines the progress made towards more efficacious combination therapies and their evaluation in clinical trials. The limitations and challenges that remain to harness the full potential of reovirus are also discussed. Oncolytic virotherapy (OVT) has received significant attention in recent years, especially since the approval of talimogene Laherparepvec (T-VEC) in 2015 by the Food and Drug administration (FDA). Mechanistic studies of oncolytic viruses (OVs) have revealed that most, if not all, OVs induce direct oncolysis and stimulate innate and adaptive anti-tumour immunity. With the advancement of tumour modelling, allowing characterisation of the effects of tumour microenvironment (TME) components and identification of the cellular mechanisms required for cell death (both direct oncolysis and anti-tumour immune responses), it is clear that a “one size fits all” approach is not applicable to all OVs, or indeed the same OV across different tumour types and disease locations. This article will provide an unbiased review of oncolytic reovirus (clinically formulated as pelareorep), including the molecular and cellular requirements for reovirus oncolysis and anti-tumour immunity, reports of pre-clinical efficacy and its overall clinical trajectory. Moreover, as it is now abundantly clear that the true potential of all OVs, including reovirus, will only be reached upon the development of synergistic combination strategies, reovirus combination therapeutics will be discussed, including the limitations and challenges that remain to harness the full potential of this promising therapeutic agent.
登录
查看更多内容
在复发性卵巢，输卵管或腹膜癌中，每周紫杉醇与每周紫杉醇的随机IIB评估：NRG肿瘤学/妇科肿瘤学组研究。
影响因子：
4.7
作者：
Cohn DE;Sill MW;Walker JL;O'Malley D;Nagel CI;Rutledge TL;Bradley W;Richardson DL;Moxley KM;Aghajanian C
通讯作者：
Aghajanian C
影响因子：
10.1
作者：
Berkeley, Robert A.;Steele, Lynette R.;Ilett, Elizabeth J.
通讯作者：
Ilett, Elizabeth J.
DOI：
10.1073/pnas.82.1.24
发表时间：
1985-01-01
影响因子：
11.1
作者：
CASHDOLLAR, LW;CHMELO, RA;JOKLIK, WK
通讯作者：
JOKLIK, WK
影响因子：
3.7
作者：
Christian SL;Zu D;Licursi M;Komatsu Y;Pongnopparat T;Codner DA;Hirasawa K
通讯作者：
Hirasawa K
影响因子：
11.5
作者：
Comins, Charles;Spicer, James;Pandha, Hardev S.
通讯作者：
Pandha, Hardev S.